Immunostimulatory sequences of DNA and conjugates in the treatment of allergic rhinitis.
Therapeutic strategies based on the use of immunostimulatory sequences of DNA containing a CpG motif (also known as ISS DNA, or CpG DNA) are focused on minimizing the allergenicity of immunotherapy while improving its effectiveness. Several ISS DNA-based methods of immunization (ISS DNA alone, ISS DNA conjugated to a protein allergen) have shown promise in animal models of asthma, and some of these ISS DNA-based therapies have entered clinical trials. These ongoing clinical trials will help to determine whether any of these ISS DNA-based therapies are safe and effective to use in subjects with allergic rhinitis and asthma.
Broide
David H
DH
Department of Medicine, University of California San Diego, 9500 Gilman Drive, MC 0635, La Jolla, CA 92093, USA. dbroide@ucsd.edu
D000818:Animals; D001249:Asthma / Q000628:therapy*; D018899:CpG Islands; D004247:DNA / Q000276:immunology / Q000627:therapeutic use*; D006801:Humans; D007167:Immunotherapy; D006255:Rhinitis, Allergic, Seasonal / Q000628:therapy*; D018418:Th2 Cells / Q000276:immunology; D019444:Vaccines, DNA / Q000276:immunology / Q000627:therapeutic use
D019444:Vaccines, DNA; D004247:DNA